Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio

 
• By Ian Haydock, Brian Yang, Jung Won Shin, Vibha Ravi, and Joseph Haas

US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.

Asia Deal Watch
• Source: Alamy

More from Deals

More from Business